Klotho ||| S:0 E:6 ||| NNP
,  ||| S:6 E:8 ||| ,
phosphate  ||| S:8 E:18 ||| NN
and  ||| S:18 E:22 ||| CC
inflammation ||| S:22 E:34 ||| CD
/ ||| S:34 E:35 ||| CD
ageing  ||| S:35 E:42 ||| NN
in  ||| S:42 E:45 ||| IN
chronic  ||| S:45 E:53 ||| JJ
kidney  ||| S:53 E:60 ||| NN
disease  ||| S:60 E:68 ||| NN
Evidence  ||| S:68 E:77 ||| NN
is  ||| S:77 E:80 ||| VBZ
emerging  ||| S:80 E:89 ||| VBG
for  ||| S:89 E:93 ||| IN
the  ||| S:93 E:97 ||| DT
inflammatory  ||| S:97 E:110 ||| JJ
nature  ||| S:110 E:117 ||| NN
of  ||| S:117 E:120 ||| IN
many  ||| S:120 E:125 ||| JJ
ageing-associated  ||| S:125 E:143 ||| JJ
diseases ||| S:143 E:151 ||| NNS
,  ||| S:151 E:153 ||| ,
including  ||| S:153 E:163 ||| VBG
atherosclerosis ||| S:163 E:178 ||| NN
,  ||| S:178 E:180 ||| ,
vascular  ||| S:180 E:189 ||| JJ
calcification ||| S:189 E:202 ||| NN
,  ||| S:202 E:204 ||| ,
diabetes  ||| S:204 E:213 ||| NN
and  ||| S:213 E:217 ||| CC
chronic  ||| S:217 E:225 ||| JJ
kidney  ||| S:225 E:232 ||| NN
disease  ||| S:232 E:240 ||| NN
( ||| S:240 E:241 ||| -LRB-
CKD ||| S:241 E:244 ||| NNP
) ||| S:244 E:245 ||| -RRB-
,  ||| S:245 E:247 ||| ,
among  ||| S:247 E:253 ||| IN
others ||| S:253 E:259 ||| NNS
.  ||| S:259 E:261 ||| .
Ageing  ||| S:261 E:268 ||| VBG
itself  ||| S:268 E:275 ||| PRP
results  ||| S:275 E:283 ||| VBZ
in  ||| S:283 E:286 ||| IN
chronic  ||| S:286 E:294 ||| JJ
low-grade  ||| S:294 E:304 ||| JJ
inflammation  ||| S:304 E:317 ||| NN
that  ||| S:317 E:322 ||| WDT
promotes  ||| S:322 E:331 ||| VBZ
end-organ  ||| S:331 E:341 ||| JJ
damage ||| S:341 E:347 ||| NN
.  ||| S:347 E:349 ||| .
Inflammatory  ||| S:349 E:362 ||| JJ
organ  ||| S:362 E:368 ||| NN
damage ||| S:368 E:374 ||| NN
,  ||| S:374 E:376 ||| ,
in  ||| S:376 E:379 ||| IN
turn ||| S:379 E:383 ||| NN
,  ||| S:383 E:385 ||| ,
may  ||| S:385 E:389 ||| MD
contribute  ||| S:389 E:400 ||| VB
to  ||| S:400 E:403 ||| TO
inflammation ||| S:403 E:415 ||| VB
.  ||| S:415 E:417 ||| .
Recent  ||| S:417 E:424 ||| JJ
research  ||| S:424 E:433 ||| NN
has  ||| S:433 E:437 ||| VBZ
identified  ||| S:437 E:448 ||| VBN
the  ||| S:448 E:452 ||| DT
kidney-secreted  ||| S:452 E:468 ||| JJ
hormone  ||| S:468 E:476 ||| NN
Klotho  ||| S:476 E:483 ||| NNS
as  ||| S:483 E:486 ||| IN
a  ||| S:486 E:488 ||| DT
central  ||| S:488 E:496 ||| JJ
player  ||| S:496 E:503 ||| NN
at  ||| S:503 E:506 ||| IN
the  ||| S:506 E:510 ||| DT
ageing-inflammation  ||| S:510 E:530 ||| JJ
interface ||| S:530 E:539 ||| NN
.  ||| S:539 E:541 ||| .
Thus ||| S:541 E:545 ||| RB
,  ||| S:545 E:547 ||| ,
systemic  ||| S:547 E:556 ||| JJ
or  ||| S:556 E:559 ||| CC
local  ||| S:559 E:565 ||| JJ
renal  ||| S:565 E:571 ||| FW
inflammation  ||| S:571 E:584 ||| FW
decreases  ||| S:584 E:594 ||| FW
kidney  ||| S:594 E:601 ||| FW
Klotho  ||| S:601 E:608 ||| FW
expression ||| S:608 E:618 ||| FW
.  ||| S:618 E:620 ||| .
Klotho  ||| S:620 E:627 ||| NNP
down-regulation  ||| S:627 E:643 ||| NNP
may  ||| S:643 E:647 ||| MD
be  ||| S:647 E:650 ||| VB
induced  ||| S:650 E:658 ||| VBN
by  ||| S:658 E:661 ||| IN
specific  ||| S:661 E:670 ||| JJ
cytokines  ||| S:670 E:680 ||| JJ
such  ||| S:680 E:685 ||| JJ
as  ||| S:685 E:688 ||| IN
tumour  ||| S:688 E:695 ||| JJ
necrosis  ||| S:695 E:704 ||| JJ
factor-α  ||| S:704 E:713 ||| JJ
or  ||| S:713 E:716 ||| CC
TWEAK  ||| S:716 E:722 ||| NNP
through  ||| S:722 E:730 ||| IN
the  ||| S:730 E:734 ||| DT
canonical  ||| S:734 E:744 ||| JJ
activation  ||| S:744 E:755 ||| NN
of  ||| S:755 E:758 ||| IN
the  ||| S:758 E:762 ||| DT
inflammatory  ||| S:762 E:775 ||| JJ
transcription  ||| S:775 E:789 ||| JJ
factor  ||| S:789 E:796 ||| NN
nuclear  ||| S:796 E:804 ||| JJ
factor  ||| S:804 E:811 ||| NN
kappa  ||| S:811 E:817 ||| VBD
B  ||| S:817 E:819 ||| NNP
( ||| S:819 E:820 ||| -LRB-
NFκB ||| S:820 E:824 ||| NNP
)  ||| S:824 E:826 ||| -RRB-
and ||| S:826 E:829 ||| CC
,  ||| S:829 E:831 ||| ,
specifically  ||| S:831 E:844 ||| RB
RelA ||| S:844 E:848 ||| JJ
.  ||| S:848 E:850 ||| .
In  ||| S:850 E:853 ||| IN
addition ||| S:853 E:861 ||| NN
,  ||| S:861 E:863 ||| ,
inflammatory  ||| S:863 E:876 ||| JJ
cytokines  ||| S:876 E:886 ||| NNS
lead  ||| S:886 E:891 ||| VBP
to  ||| S:891 E:894 ||| TO
the  ||| S:894 E:898 ||| DT
epigenetic  ||| S:898 E:909 ||| JJ
inactivation  ||| S:909 E:922 ||| NN
of  ||| S:922 E:925 ||| IN
Klotho  ||| S:925 E:932 ||| NNP
transcription ||| S:932 E:945 ||| NN
.  ||| S:945 E:947 ||| .
Klotho  ||| S:947 E:954 ||| VBG
itself  ||| S:954 E:961 ||| PRP
has  ||| S:961 E:965 ||| VBZ
antioxidant  ||| S:965 E:977 ||| VBN
and  ||| S:977 E:981 ||| CC
anti-inflammatory  ||| S:981 E:999 ||| JJ
properties  ||| S:999 E:1010 ||| NNS
and  ||| S:1010 E:1014 ||| CC
the  ||| S:1014 E:1018 ||| DT
canonical  ||| S:1018 E:1028 ||| JJ
NFκB  ||| S:1028 E:1033 ||| JJ
component  ||| S:1033 E:1043 ||| NN
RelA  ||| S:1043 E:1048 ||| NN
is  ||| S:1048 E:1051 ||| VBZ
one  ||| S:1051 E:1055 ||| CD
of  ||| S:1055 E:1058 ||| IN
its  ||| S:1058 E:1062 ||| PRP$
targets ||| S:1062 E:1069 ||| NNS
.  ||| S:1069 E:1071 ||| .
Klotho  ||| S:1071 E:1078 ||| NNP
is  ||| S:1078 E:1081 ||| VBZ
a  ||| S:1081 E:1083 ||| DT
key  ||| S:1083 E:1087 ||| JJ
regulator  ||| S:1087 E:1097 ||| NN
of  ||| S:1097 E:1100 ||| IN
phosphate  ||| S:1100 E:1110 ||| JJ
balance  ||| S:1110 E:1118 ||| NN
and  ||| S:1118 E:1122 ||| CC
a  ||| S:1122 E:1124 ||| DT
role  ||| S:1124 E:1129 ||| NN
of  ||| S:1129 E:1132 ||| IN
phosphate  ||| S:1132 E:1142 ||| NN
in  ||| S:1142 E:1145 ||| IN
ageing  ||| S:1145 E:1152 ||| NN
has  ||| S:1152 E:1156 ||| VBZ
been  ||| S:1156 E:1161 ||| VBN
shown ||| S:1161 E:1166 ||| VBN
.  ||| S:1166 E:1168 ||| .
However ||| S:1168 E:1175 ||| RB
,  ||| S:1175 E:1177 ||| ,
the  ||| S:1177 E:1181 ||| DT
potential  ||| S:1181 E:1191 ||| JJ
relationship  ||| S:1191 E:1204 ||| NN
between  ||| S:1204 E:1212 ||| IN
phosphate  ||| S:1212 E:1222 ||| NN
and  ||| S:1222 E:1226 ||| CC
inflammation  ||| S:1226 E:1239 ||| NN
requires  ||| S:1239 E:1248 ||| VBZ
further  ||| S:1248 E:1256 ||| JJ
clarification ||| S:1256 E:1269 ||| NN
.  ||| S:1269 E:1271 ||| .
A  ||| S:1271 E:1273 ||| DT
correct  ||| S:1273 E:1281 ||| JJ
understanding  ||| S:1281 E:1295 ||| NN
of  ||| S:1295 E:1298 ||| IN
these  ||| S:1298 E:1304 ||| DT
interactions  ||| S:1304 E:1317 ||| NN
may  ||| S:1317 E:1321 ||| MD
lead  ||| S:1321 E:1326 ||| VB
to  ||| S:1326 E:1329 ||| TO
the  ||| S:1329 E:1333 ||| DT
design  ||| S:1333 E:1340 ||| NN
of  ||| S:1340 E:1343 ||| IN
novel  ||| S:1343 E:1349 ||| JJ
therapeutic  ||| S:1349 E:1361 ||| JJ
approaches  ||| S:1361 E:1372 ||| NNS
to  ||| S:1372 E:1375 ||| TO
CKD  ||| S:1375 E:1379 ||| NNP
and  ||| S:1379 E:1383 ||| CC
CKD-related  ||| S:1383 E:1395 ||| JJ
inflammatory  ||| S:1395 E:1408 ||| NN
and  ||| S:1408 E:1412 ||| CC
ageing  ||| S:1412 E:1419 ||| JJ
features  ||| S:1419 E:1428 ||| NNS
as  ||| S:1428 E:1431 ||| IN
well  ||| S:1431 E:1436 ||| RB
as  ||| S:1436 E:1439 ||| RB
to  ||| S:1439 E:1442 ||| TO
inflammation ||| S:1442 E:1454 ||| CD
/ ||| S:1454 E:1455 ||| CD
ageing  ||| S:1455 E:1462 ||| NN
in  ||| S:1462 E:1465 ||| IN
general ||| S:1465 E:1472 ||| JJ
.  ||| S:1472 E:1474 ||| .
